Stockreport

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal [Yahoo! Finance]

Syros Pharmaceuticals, Inc.  (SYRS) 
Last syros pharmaceuticals, inc. earnings: 3/5 06:57 am Check Earnings Report
US:NASDAQ Investor Relations: ir.syros.com
PDF higher-risk myelodysplastic syndrome (HR-MDS) failed to meet the primary endpoint of complete response (CR) rate. Tamibarotene is Syros' proprietary, oral, selective RAR [Read more]